Mode
Text Size
Log in / Sign up

Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis and axial spondyloarthritis

Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis an…
Photo by Logan Voss / Unsplash
Key Takeaway
Note genetic variants associated with inflammatory markers in rheumatoid arthritis and axial spondyloarthritis.

This meta-analysis examines genetic variants (SNPs) in three large European populations, including the UK Biobank, FinnGen, and REPAIR, involving 12,660 rheumatoid arthritis cases, 2,446 radiographic axial spondyloarthritis cases, and over 530,000 shared controls. The primary objective was the identification of new overlapping and disease-specific genetic risk factors, supported by secondary outcomes such as functional characterization through cytokine and protein assessments and eQTL analyses.

Specific genetic associations were identified, including the GRM4rs2495964G variant linked to decreased CCL25 levels (p = 0.00030) and the ITPR3rs9469540T variant linked to reduced IL10 production after LPS stimulation (p = 1.3×10−4). Additionally, the ZNF322rs6901425G allele was associated with reduced TNFB (p = 9.60×10−4) and increased TGM2 levels (p = 3.00×10−4). The BTN2A1rs1977199A allele demonstrated a protective effect in rheumatoid arthritis (OR = 0.93) but increased risk in radiographic axial spondyloarthritis (OR = 1.23), alongside associations with reduced IL22 (p = 0.00016) and elevated HO-1 in obese individuals (p = 6.73×10−6).

Further analysis indicated that BTN3A2rs9393716G and H2BC11rs66462181C variants increased rheumatoid arthritis risk but were protective in radiographic axial spondyloarthritis, linking to decreased HO-1 and IL6 (p = 2.43×10−5, 3.287×10−4, 1.18×10−4). The study offers insights for disease stratification and therapeutic targeting. As a meta-analysis of observational genetic data, these findings describe associations rather than confirming causal mechanisms or clinical outcomes.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
This study conducted a meta-analysis across three large European cohorts (UKBB, FinnGen, and REPAIR), including 12,660 rheumatoid arthritis (RA) cases, 2,446 radiographic axial spondyloarthritis (r-axSpA) cases, and over 530,000 shared controls. Ten independent SNPs in CARMIL1, GRM4, ITPR3, PRSS16, ZNF322, HTT, IKZF1, MANEA, and MGAM2 were analyzed, and functional characterization was performed through cytokine and protein assessments as well as eQTL analyses. Ten independent SNPs were significantly associated with both RA and r-axSpA. Risk alleles included HTTrs363075A, IKZF1rs12718261A, MANEArs72920280T, and MGAM2rs73158426G, while CARMIL1rs72831267C, GRM4rs2495964G, ITPR3rs77601296A, ITPR3rs9469540T, PRSS16rs72843633T, and ZNF322rs6901425G had protective effects. Functional analysis showed that GRM4rs2495964G was linked to decreased CCL25 levels (p = 0.00030), and ITPR3rs9469540T to reduced IL10 production after LPS stimulation (p = 1.3×10−4). The ZNF322rs6901425G allele was associated with reduced TNFB and increased TGM2 levels (p = 9.60×10−4 and p = 3.00×10−4), both involved in immune signaling and tissue remodeling. Disease-specific associations were found in BTN2A1, BTN3A2, and H2BC11. The BTN2A1rs1977199A allele was protective in RA (OR = 0.93) but increased r-axSpA risk (OR = 1.23), and was associated with reduced IL22 (p = 0.00016) and elevated HO-1 in obese individuals (p = 6.73×10−6). In contrast, BTN3A2rs9393716G and H2BC11rs66462181C increased RA risk but were protective in r-axSpA, linked to decreased HO-1 and IL6 (p = 2.43×10−5, 3.287times;10−4, 1.18×10−4). These SNPs also acted as eQTLs for immune-related genes such as BTN3A2, HMGN4, and TRIM38. Our findings highlight novel shared and disease-specific variants and key immunoregulatory mediators—IL10, IL22, IL6, CCL25, and HO-1—offering insights for disease stratification and therapeutic targeting.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.